2026 Poster Presentations Coming in January
Here is a reminder of the 2025 Poster Presentations:
Poster Session A: Tuesday - Wednesday (morning)
A01: Co-Evolution of SARS-CoV-2 and a Human Therapeutic mAb to Neutralize All Variants to Date, Presented by Kevin E., Abwiz Bio, Inc.
A02: Complementary Methodologies for Size Heterogeneity Analysis of Antibody Impurities, Presented by Kyle L., Agilent Technologies, Inc.
A03: Next-Generation ADC Manufacturing Technology: AJICAP® Site-Specific Conjugation and Stable Linker, Presented by Hiroki I., Ajinomoto Co., Inc.
A04: Corynex®: Suitable Protein Expression System for Long-Chain Peptides Including GLP-1 Analogues, Presented by Yukari K., Ajinomoto Co., Inc.
A05: High-Throughput Cell Culture Process Assessment for Improving Productivity of Hetero-IgG Molecules, Presented by Diandra M., Amgen, Inc.
A06: Implementing High-Throughput Screening for the Formulation Development of Biologics, Presented by Farzad M., Amgen, Inc.
A07: A New HEK-293 Transient Expression Platform for Early Material Generation and High Efficiency In Cellulo Biotinylation, Presented by Gregory B., Antibody Design Laboratories
A08: High-Throughput Signal Peptide Optimization to Boost Protein Production, Presented by Leila R., Avenue Biosciences
A09: BASF Bioservices: Case Studies in Protein Engineering, Automated Screening and HTP Diversity Profiling, Presented by Michael L., BASF Corporation
A10: Simplified and Humanized: Empowering Humanized Antibody Discovery with AbDrop™ Solution, Presented by Eric C., Biointron
A11: Saving Lives Innovative Ion Exchange Resin Therapeutic Applications, Presented by Sharon B., Bio-Rad Laboratories, Inc.
A12: Maximizing Productivity and Efficiency with Continuous Chromatography on the NGC System, Presented by Heidi J., Bio-Rad Laboratories, Inc.
A13: Elevating Protein Purification Efficiency: Transitioning from Manual Techniques to Automated Platforms, Presented by Gabrielle K., Biotage
A14: Accelerate Kinetic Screening and Epitope Characterization of Antibody Libraries with High Throughput SPR, Presented by Chris S., Carterra, Inc.
A15: Full Antigen Kinetics of Fabs Directly from Crude Periplasmic Extracts on an Anti-CH1 Capture Surface, Presented by Chris S., Carterra, Inc.
A16: High-Affinity Nanobodies Targeting Mesothelin (MSLN): In-Silico Design and Experimental Validation for TNBC Therapeutics, Presented by Mehedi H., Delaware State University
A17: Development of Semi-Automated Magnetic Bead Purification Platform for Multi-Milligram Material Generation, Presented by Joanne C., Denali Therapeutics
A18: Bispecific Antibodies Targeting the ENG-ALK1-BMPRII Axis as a Novel Approach for the Treatment of HHT, Presented by Aysheh A., Diagonal Therapeutics
A19: High Throughput Solutions for Large Antibody Panels Evaluation, Presented by Joao S., FairJourney Biologics SA
A20: FcRN Binding Assessment of IgG Fc Variants: A 360° View with Affinity, Kinetics and In Vitro Testing, Presented by Maria V., FairJourney Biologics SA
A21: Influence of 5’-UTR and N-Terminal Region of ORF on the Efficiency of Protein Synthesis in a Reconstituted Cell-Free Protein Synthesis System (PUREfrex®), Presented by Takashi K., Genefrontier
A22: Comprehensive Solutions for Protein and Antibody Drug Development, Presented by Roumen B., GenScript USA, Inc.
A23: Streamlining Bispecific Antibody Development: GenScript's Integrated Approach to Accelerating Next-Generation Therapeutics, Presented by Amanda G., GenScript USA, Inc.
A24: Revolutionizing Research with Automated Maxi-Scale Plasmid Purification, Presented by Rouba N., GenScript USA, Inc.
A25: Digital Membrane Chromatography (DMC): Gentle Purification of IgG1 from Cell Culture Without Buffer Exchange, Presented by Anna K., i3 Membrane Corporation
A26: Empirical, Solution-State Epitope/Paratope Interactions to Constrain In Silico Models for Antibody Design and Targeted Engineering, Presented by Dan B., Immuto Scientific
A27: Maximizing Efficiency and Predictability in Bioprocess Development Using a Versatile inGenius® Platform, Presented by Masha K. & Rita C., Ingenza Ltd.
A28: Automated High-Throughput Protein and Plasmid Purification with Integrated Buffer Exchange, Presented by Anusha C., Integrated Micro-Chromatography Systems (IMCS)
A29: Enabling Rapid Bispecific Antibody Discovery with Invenra’s B-Body Platform, Presented by Luigi V., Invenra, Inc.
A30: Targeted NGS and Peptide Mapping Unite in Uncovering Low-Level Sequence Variants to De-Risk the Pipeline, Presented by Elizabeth S., Johnson & Johnson Innovative Medicine
A31: New Transposase Integration in SUREtechnology Platform™ Takes High-Performance Clones to the Next-Level, Presented by Quentin A., KBI Biopharma
A32: EZ Tag: A New Solution for Difficult-to-Express Proteins, Presented by Sangyong J., Korea Advanced Institute of Science and Technology (KAIST)
A33: Development of a Higher-Energy Collisional Dissociation Tandem Mass Spectrometry Approach to Identify the Positions of D-Amino Acids in Peptide Epimers Formed During Peptide Drug Synthesis, Presented by Pao-Chi L., National Cheng Kung University
A34: A Computational Framework for Assessing Antibody Mutations Aimed at Enhancing Their Half-Life, Presented by Myungjin L., National Institutes of Health, National Institute of Allergy and Infectious Diseases
A35: DNA to Assay-Ready Proteins in 48 hours. Rapid Protein Expression and Purification on the eProtein Discovery™ System and Binding Confirmation on Biacore™ SPR System, Presented by Michael C., Nuclera
A36: Screen, Scale, Capture, Characterize: Rapid Protein Production and Characterization of Drug-Target Interactions, Presented by Aujan M., Nuclera
A37: A Rational Protein Engineering Approach to Enhance a Self-Removing Purification Tag, Presented by Sabat GS., Ohio State University
A38: Early Biophysical Developability Assessment of Antibody-Drug Conjugates Using Microplate Assays in High Throughput, Presented by Sebastian G., PAIA Biotech GmbH
A39: Development of the SupersonicIEF™ Method for the Maurice™ Platform, Presented by Surashree K., ProteinSimple, a Bio-Techne brand
A40: Mimic Antibodies and How to Find Them, Presented by Brennan AK., Roche Diagnostics GmbH
A41: Performance Benchmarking of Commercial Cell-Free Expression Platforms, Presented by Mainak DG., Sartorius
A42: How to Use Cold-Accelerated Studies to Model Aggregation of Antibodies During Storage, Presented by Miguel R., Smartfreez
A43: Automating the ExpiCHO Expression System for mAb, Fc Fusion and Bi-Specific Protein Production, Presented by Collin R., Thermo Fisher Scientific
A44: Innovative Capture Purification Solutions for Therapeutic Antibody Manufacturing, Presented by Summer S., Thermo Fisher Scientific
A45: Using Ontologies to Make Bioassay Protocols Machine Readable, Presented by Christopher S., University of Edinburgh
A46: A Four-Compound Remedy AGILe Attenuates Ischemic Myocardial Injury via Targeting TNF-α/NF-κB Pathway, Presented by Xiuying Z., University of Hong Kong
A47: Engineering Potent Antibody Responses Against Human Cytomegalovirus, Presented by Alison L., University of Texas at Austin
A48: Principles and Practice Using SEC for Reliable Biotherapeutic Peptides Analyses, Presented by Bill W., Waters Corporation
A49: TFC Quick ‘n’ Clean: Next-Gen Platform for High-Throughput Production of True Four-Chain BsAbs, Presented by Kevin L., WuXi Biologics
A50: Characterizing Quality Attributes of GLP-1 Analogs by Light Scattering, Presented by Emily D., Wyatt Technology
A51: Combining Advanced Peptide Screening Methods to Identify Peptide Candidates for Peptide Radionuclide Conjugates Development, Presented by Timo X., Zonsen PepLib Biotech, Inc.
A52: High-Throughput Antibody Developability Data Generation Platform for Drug Discovery and AI/ML Model Training, Presented by Rich C., Ginkgo BioWorks, Inc.
Poster Session B: Wednesday (afternoon) - Thursday
B01: Preclinical Development of Cis-Acting, Affinity Tuned IL-21 Immunocytokines for Cancer Immunotherapy, Presented by Jacob B., A-Alpha Bio
B02: Pathological Research in Diseases Is Improved with Studies with Inflammation-Related Approaches, Presented by Huan-Yuan C., Academia Sinica
B03: Design and Development Strategy for Target Proteins Used in Antibody Drug Discovery, Presented by Peter H., ACROBiosystems
B04: Characterization Tools for Injectable Products: Navigating Alternate Primary Container Selection for a High Concentration mAb Late-Stage Program, Presented by Rebekah C., AstraZeneca
B05: A Proven and Reliable Alpaca VHH Antibody Discovery Platform, Presented by Eric C., Biointron
B06: Unique Antibody Display Technology to Break Barriers in Biotherapeutics and Beyond for Multispecific Antibodies, Presented by Kohei K., Chiome Bioscience, Inc.
B07: Next Generation Copolymers for the Characterization of Membrane Proteins in Near-Native Conditions, Presented by Barbara M., Cube Biotech
B08: Methods to Reduce Anti-Drug Antibody Formation by Removing T Cell Epitopes, Presented by Yifan S., Cyrus Biotechnology
B09: Use of Drosophila S2 Cells for Production of highly Immunogenic Antigens, Presented by Max S., ExpreS2ion Biotechnologies
B10: Machine Learning Guided Interaction Analysis, Presented by James W., Fluidic Sciences
B11: Membrane, Resin, and Impact to Product: Overcoming Barriers to Adopting Membrane Technology by Demonstrating Protein A Affinity Capture Step Product Quality and Process Characteristic Similarity, Presented by Jeffrey C., W.L. Gore & Associates, Inc.
B12: Small-Scale Covalent Fragment Screening Coupled to High-Throughput Protein Purification to Pre-Screen for Cysteine Reactivity, Presented by Yasmin K., GSK
B13: Targeting the TGF-Beta Superfamily for the Treatment of Obesity, Presented by Cory S., iBio, Inc.
B14: High-Throughput Screening of Bispecific ADCs: Evaluation of a 5-Target Matrix Using the B-Body Platform, Presented by Luigi V., Invenra, Inc.
B15: Insights into Technical Development of LILRB1 and LILRB2 Cross-Specific Antibody IOMX-0675 On Its Way to the Clinic, Presented by Stefan K., iOmx Therapeutics AG
B16: A Neural Network to Predict the Rosetta Energies of Protein Residues to Inject into AI Antibody Structure Prediction, Presented by Britnie C., Johns Hopkins University
B17: Evaluating the Biological Realism of IgLM-Generated Antibody Sequences for Drug Development, Presented by Natalia R., Johns Hopkins University
B18: Are Ab Language Models Learning Heavy-Light Pairing Semantics?, Presented by Donovan V., Johns Hopkins University
B19: GPCR VLPs & Nanodiscs for Drug Discovery, Presented by Maggie G., KACTUS
B20: Transforming Tumor Research: Engineering MHCs as Versatile Reagents, Presented by Sarah R., KACTUS
B21: Strategy and Workflow for Pre-Formulation Development at KBI Biopharma, Presented by Christopher R., KBI Biopharma
B22: From Weeks to Hours: Accelerated Virus Titer Determination with Miniaturized IHC Assay, Presented by Sneha R., Kemp Proteins
B23: AI-Driven Paratope Mapping for Antibody Discovery: Enhancing Selection Through the KisoSeek™ Platform, Presented by Chris C., KisoJi Biotechnology
B24: Development of Bispecific Inhibitors for the Treatment of Geographic Atrophy, Presented by Catherine C., Kodiak Sciences
B25: Efficient Method for the Expression and Purification of Recombinant Human Procalcitonin (hPCT) with a Precise Sequence, Using a Two-Step Affinity Chromatography Process, Presented by Masataka N., Kyokuto Pharmaceutical Industrial Co., Ltd.
B26: Development of scFv-Based Affinity Chromatographic Resins by CDR-Grafting Technology, Presented by Yoichi K., Kyoto Institute of Technology
B27: Synthesis of Chimeric Antigen Receptor Nanolipoproteins for T Cell Delivery and Immunotherapy, Presented by Claire R., Lawrence Livermore National Laboratory
B28: Clone-Wise Biomarker Discovery Enabled Through Single-Cell RNA Sequencing, Presented by Alessandro D., Lonza AG
B29: Novel Synthetic Production Phase Promoter for Enhanced Titre, Product Quality and Expression Stability in CHO Cells, Presented by Bernadette S., Lonza Biologics Plc
B30: Introducing NEBExpress® Salt Active Nuclease for Nucleic Acid Removal in Purification Workflows, Presented by Carine RI., New England Biolabs
B31: Characterizing Apolipoprotein E: Biophysical Insights into Its Role in Late-Onset Alzheimer’s Disease, Presented by Yun-Ting H., Tenvie Therapeutics
B32: A Novel icIEF and Digital SPR Workflow for Correlating the Charge Structure to the Function of a Bispecific Antibody, Presented by Michael P., Nicoya Lifesciences
B33: Characterizing the In Vitro and In Vivo Efficacy of Staphylococcus aureus Monoclonal Antibodies Against Secreted Prothrombin-Activating Virulence Factors, Presented by Ting W., Odyssey Systems
B34: Optimizing Protein Databases for CHO SWATH-MS Spectral Library Construction: Enhanced Detection and Quantification of High-Risk Host Cell Proteins, Presented by Tomoko M., Osaka University
B35: Developability Assessment for Nonspecificity and Polyspecificity in High-Throughput Bead-Based Assays in Microplates, Presented by Aris P., PAIA Biotech GmbH
B36: Cell-Based Luminescent Reporter Bioassays for Immunotherapies Targeting Macrophage Effector Functions, Presented by Steven E., Promega Corporation
B37: High Throughput Assays to Evaluate the Stability of a Bispecific Antibody Using Forced Degradation, Presented by James G., Revvity
B38: A Single Platform for Complete Characterization of Plasmid DNA, Presented by James G., Revvity
B39: Antibody Optimization with Physics Based Modeling and Protein Descriptors for Machine Learning, Presented by Sunidhi L., Schrodinger, Inc.
B40: Enabling De Novo Antibody Design by Integrating ML-Based Sequence Generation with B Cell Epitope Prediction, Presented by Leigh M., Seismic Therapeutic
B41: Modular Multi-Objective Optimization Method for Generative Design of Proteases with Therapeutic Potential, Presented by June S., Seismic Therapeutic
B42: Immunogenicity Prediction with Dual Attention Enables Vaccine Target Selection, Presented by Huang L., Shanghai Matwings Technology Co., Ltd.
B43: A General Temperature-Guided Language Model to Design Proteins of Enhanced Stability and Activity, Presented by Huang L., Shanghai Matwings Technology Co., Ltd.
B44: High-Throughput and Low Cost Production and Capture Purification of scFv/VHH Libraries on SPOC SPR Biosensor Chips for Affinity Maturation Cycles, Presented by Lydia G., SPOC Proteomics
B45: From Seaweed to Consumer Goods: Evaluating Antioxidant Efficacy in Skincare Products, Presented by Hazel K., Stanford University
B46: Power Meets Precision: HTP Antibody Production with Expi™ Protein Expression Systems & GeneArt HTP Antibody Production, Presented by Richard A., Thermo Fisher Scientific
B47: Overcoming Aggregate Removal Challenges in the Therapeutic Antibody Purification Workflow, Presented by Cole D., Thermo Fisher Scientific
B48: Advanced Affinity Chromatograph Tools for Bispecific Antibody Purification, Presented by David H., Thermo Fisher Scientific
B49: Leveraging Novel In Vivo Datasets to Generate Machine Learning Models Predicting Protein Aggregation and Developability, Presented by Conor M., University of Leeds
B50: Prediction of Antibody Properties for Optimization: Leveraging High-Throughput Data Collection System of Thermal Stability and Interaction Kinetics, Presented by Sae I., University of Tokyo
B51: T Cell Mate: An Innovative High-Titer CHO Platform Setting a New Standard for T-Cell-Related Protein Production, Presented by Pavel R., WuXi Biologics
Additional Virtual Posters
V1: Accurate and Efficient Chemical Similarity Search Tool and Contact-Distribution- Matching Method Jointly Identify FDA-Approved Drugs that Modulate SARS- CoV2 -1PRF and Suppress Its Replication, Presented by Ahmed R., National Tsing Hua University
V2: Learning Protein Fitness Landscapes with Deep Mutational Scanning Data from Multiple Sources, Presented by Lin C., Shanghai Institute of Materia Medica